Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) highlighted preclinical results for EB-003, a dual 5-HT2A/5-HT1B modulator. A single dose significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05), indicating a rapid reduction in conditioned fear in a validated PTSD model.
The company positioned EB-003 as a next-generation neuroplastogen targeting neuroplasticity and mood signaling pathways as interest in psychedelic-inspired therapies grows.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) said CEO Joseph Tucker, Ph.D., will join a panel at Needham’s Virtual Psychedelics Forum on Monday, April 27, 1:00 PM - 2:00 PM ET.
The panel topic is "Beyond TRD: Non-Hallucinogens and New Indications". Management will hold one-on-one investor and partner meetings to review clinical strategy and anticipated milestones. Registration is available online.
Enveric Biosciences (NASDAQ: ENVB) closed a private placement priced at-the-market on April 17, 2026, raising approximately $5.0 million in gross proceeds from the sale of 2,222,223 shares (or pre-funded warrants) and accompanying warrants at $2.25 per share.
The offering includes Series I warrants and short-term Series J warrants to buy up to 2,222,223 shares each at a $2.00 exercise price, potentially providing an additional $8.9 million if fully exercised; the company intends to use net proceeds for product development, working capital and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced a private placement priced at-the-market to raise approximately $5.0 million upfront and up to $8.9 million additional if warrants are fully exercised. The offering includes 2,222,223 shares and Series I and J warrants exercisable at $2.00.
Closing expected on or about April 17, 2026; H.C. Wainwright is placement agent. Net proceeds to fund product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced that U.S. Patent No. 12,577,232 was issued on March 17, 2026, covering its EVM301 Series of N-heterocycle substituted tryptamine derivatives.
The patent claims chemical compounds, pharmaceutical formulations, and methods for treating brain neurological disorders and expands coverage alongside U.S. Patent No. 12,338,231. Enveric cites lead candidate EB-003 and says it is progressing toward an IND submission and a first-in-human Phase 1 trial. The company reports a patent estate of 27 issued U.S. patents and approximately 60 pending national and international applications.
Enveric Biosciences (NASDAQ: ENVB) reported fourth-quarter and year‑end 2025 results and operational updates on March 27, 2026. Key points: positive preclinical data for EB-003 in models of severe chronic depression and PTSD, FDA feedback allowing a streamlined IND plan, multiple patent issuances and a withdrawn PGR petition, manufacturing CMC milestones, a 1-for-12 reverse stock split, and $4.7M cash on hand at year‑end.
The company raised $12.2M in fiscal 2025 (including $4.9M in Q4) and reported a Q4 net loss attributable to stockholders of $4.0M (loss per share $6.12).
Enveric Biosciences (NASDAQ: ENVB) announced that the Canadian Intellectual Property Office registered five trademarks, including house marks Enveric and Enveric Biosciences.
The registrations also cover two Plus Marks for product packaging and the trademark "Next Generation Mental Health". The company said it plans an IND filing for lead molecule EB-003 with the FDA in 2026.
Enveric Biosciences (NASDAQ: ENVB) announced that the Post-Grant Review petition filed by Gilgamesh Pharmaceuticals against U.S. Patent No. 12,138,276 has been withdrawn and the PTAB granted the withdrawal, leaving no remaining challenges to the '276 patent.
The '276 patent covers halogenated psilocybin derivatives with claims relevant to bretisilocin (GM-2505), and the filing timeline cites events from August–November 2025 including AbbVie's up-to-$1.2 billion acquisition of bretisilocin from Gilgamesh.
Enveric Biosciences (NASDAQ: ENVB) reported proprietary BRET assay data showing its lead candidate EB-003 engages both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor. The company said EB-003 shows a modest β-arrestin bias versus serotonin and that both pathways are engaged at biologically relevant levels. Enveric plans additional BRET testing including the Gi pathway and continues to advance EB-003 through IND-enabling studies.